1252-Advancing Ovarian Cancer Care via Immunotherapy

This article examines the integration of targeted immunotherapies and magnetic nanoparticles (MNPs) to address the diagnostic and therapeutic hurdles of ovarian cancer. Traditional treatments often fail due to late-stage detection and high recurrence, but the synergy of nanomedicine with therapies like CAR-T cells and NK cells offers a more precise approach. MNPs enhance these treatments by serving as contrast agents for MRI, delivering drugs directly to tumors under magnetic guidance, and inducing hyperthermia to kill malignant cells. This interdisciplinary strategy aims to reverse the immunosuppressive environment of the tumor and trigger a stronger immune response. Despite challenges like biodegradability and tissue penetration, emerging solutions focus on personalized medicine and surface modifications to improve safety and efficacy. Ultimately, the authors present these hybrid technologies as a transformative path toward better survival rates and reduced systemic toxicity for patients.References:Li Y, Dou J, Fu Y, et al. Targeted immunotherapies and nanomedicines for ovarian cancer: the way forward[J]. npj Precision Oncology, 2026.前往小宇宙评论区与主播互动